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Abstract
Secondary infections are a major complication of sepsis and associated with a compro-
mised immune state, called sepsis-induced immunoparalysis. Molecular mechanisms causing
immunoparalysis remain unclear; however, changes in cellular metabolism of leukocytes have
been linked to immunoparalysis. We investigated the relation of metabolic changes to antimicro-
bial monocyte functions in endotoxin-induced immunotolerance, as a model for sepsis-induced
immunoparalysis. In this study, immunotolerance was induced in healthy males by intravenous
endotoxin (2 ng/kg, derived fromEscherichia coliO:113) administration. Before and after induction
of immunotolerance, circulating CD14+ monocytes were isolated and assessed for antimicrobial
functions, including cytokine production, oxidative burst, and microbial (Candida albicans) killing
capacity, as well metabolic responses to ex vivo stimulation. Next, the effects of altered cellular
metabolism onmonocyte functionswere validated in vitro. Ex vivo lipopolysaccharide stimulation
induced an extensive rewiring of metabolism in naive monocytes. In contrast, endotoxin-induced
immunotolerant monocytes showed no metabolic plasticity, as they were unable to adapt their
metabolism or mount cytokine and oxidative responses. Validation experiments showed that
modulation of metabolic pathways, affected by immunotolerance, influenced monocyte cytokine
production, oxidative burst, and microbial (C. albicans) killing in naive monocytes. Collectively,
these data demonstrate that immunotolerant monocytes are characterized by a loss of metabolic
plasticity and these metabolic defects impact antimicrobial monocyte immune functions. Further,
these findings support that the changed cellular metabolism of immunotolerant monocytes might
reveal novel therapeutic targets to reverse sepsis-induced immunoparalysis.
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1 INTRODUCTION
Secondary infections represent a major complication for patients
admitted to the intensive care unit (ICU) with sepsis.1 In sepsis,
hyperinflammatory responses to infection are accompanied and/or
followed by counterregulatory anti-inflammatory responses, which
can cause a dysfunctional state in which immune cells are unable
to adequately respond to pathogens.2 This phenomenon, called
sepsis-induced immunoparalysis, is associated with increased suscep-
tibility to secondary (opportunistic) infections.3 Microbial infections
in the late phase of sepsis including bacteria (e.g., Escherichia coli
and Staphylococcus aureus), fungi (e.g., Candida albicans), and viral
reactivation all illustrate the clinical significance of sepsis-induced
immunoparalysis, which is associated with increased ICU length of
stay.4–6 Moreover, the dysregulated host response is considered to be
a critical factor that contributes to the persistently high mortality in
sepsis, as a result of secondary infections.7,8
Monocytes are severely affected during immunoparalysis, and they
play a pivotal role in the host response during sepsis. A low human
leukocyte antigen–antigen D related (HLA-DR) expression on mono-
cytes coincides with an increase in nosocomial infections and higher
mortality.9,10 Another hallmark of sepsis-induced immunoparaly-
sis are impaired ex vivo monocyte cytokine responses, which are
likely a result of cellular reprogramming.11 Therefore, reversing or
preventing monocyte immunotolerance represents an attractive
strategy to improve immune function and outcome of sepsis.12 To
facilitate the development of effective therapies, the molecular mech-
anisms underlying the immunotolerant state of monocytes should
be unraveled.
In the past decade, it has become clear that during sepsis immune
function and cellular metabolism are closely interlinked.13 A previ-
ous study revealed dysfunction of cellular metabolism in immunotol-
erant monocytes.14 Recently, in vitro LPS tolerization was found to
induce prominent metabolic changes over time in THP-1 monocyte
cells.15 This study demonstrated a consecutive metabolic adaptation
of these cells during immune activation, deactivation (tolerance), and
resolution of inflammation. These findings support the notion that
metabolic rewiring after immune stimulation may be a major mecha-
nism that drives the tolerant state of immune cells. Importantly, this
study highlights the need for in vivo studies to further characterize
metabolic changes in tolerant immune cells and the impact on immune
function in parallel with this metabolic shift. A clear understanding
of the essential metabolic routes affected during immunoparalysis
and how they interfere with immune function is still lacking. This
knowledge gap needs to be bridged before effective therapies can
be developed.
In the current study, the primary aim was to better understand
the potentially defective adaptation of monocyte metabolic responses
during immunoparalysis. To this end, a standardized protocol16 of
endotoxin-induced immunotolerance was employed, where human
subjects were intravenously challenged with endotoxin (E. coli LPS)
to model sepsis-induced immunoparalysis. Monocytes were studied
before, during, and 1 week after endotoxin-induced immunotolerance
to characterize metabolic changes associated with immunotolerance
and long-lasting metabolic reprogramming following endotoxin chal-
lenge. First, the metabolic profile and immunological functions were
characterized ex vivo before immunotolerance, during immunotoler-
ance and 1 week after immunotolerance. Second, metabolic pathways
found to be affected were validated for their impact on antimicrobial
functions in naivemonocytes.
2 MATERIALS AND METHODS
2.1 Experimental human endotoxemiamodel
Experimental human endotoxemia was used as a model for sepsis-
induced immunoparalysis, as extensively described in previously
published studies.16,17 After written informed consent was obtained,
blood samples from healthy male volunteers were collected. Subjects
participated in two similarly designed endotoxemia studies (NL54870.
091.15;17 NL61136.091.16 [unpublished data]), both approved by
the local medical ethics committee. Male healthy volunteers aged 18–
35 years, all Caucasian, were screened at the Department of Intensive
Care Medicine of the Radboud University Medical Center, Nijmegen,
the Netherlands. Screening included a normal physical examination,
electrocardiography, and routine laboratory values (including serology
on HIV and hepatitis B). Exclusion criteria included febrile illness
2 weeks before baseline, a suspicion of influenza infection in the
preceding year, pre-existent (lung) disease, recent vaccination, and
usage of any prescription drugs. Subjects refrained from caffeine and
alcohol 24 h before experiments and from food 12 h before experi-
ments, as well as during experiments. In total 30 healthy volunteers
were included in the first study (NL54870.091.15).17 Of these, 15 of
volunteers were assigned to receive placebo and 15 were assigned
to the endotoxin infusion group. In the second endotoxin study
(NL61136.091.16 [unpublished data]), a total of 12 healthy volunteers
were included. Of these, 4 volunteers were in the placebo group and 8
were in the endotoxin infusion group. Participantswere hospitalized at
the Intensive Care Research Unit of the Radboud University Medical
Center, and all study-related procedures were assessed according
to the principles of the most recent revised Declaration of Helsinki.
They received either endotoxin (intravenous bolus administration
of 2 ng/kg LPS; U.S. Standard Reference Endotoxin derived from E.
coli O:113, Pharmaceutical Development Section of the National
Institutes of Health, Bethesda, MD, USA) or placebo (0.9% saline).
From the original study of 30 volunteers (NL54870.091.15),17 we
obtained blood samples at baseline (BL), 4 hours (4h), and 7 days
(7d) following endotoxin or placebo administration from 6 placebo
controls and 15 volunteers receiving endotoxin. All these samples
were analyzed for cytokine responses, and monocyte samples from
5 randomly selected volunteers receiving endotoxin were selected for
metabolic analysis. In the second study, blood samples were similarly
obtained at all aforementioned time points. Blood samples from 4
placebo and 6 endotoxin challenged subjects were available for analy-
sis of oxidative burst. Parallel, samples from the 5 volunteers receiving
endotoxin in this study were analyzed for intracellular killing capacity.
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The time points were selected based on previous in vivo endotoxemia
studies that demonstrated that 4 h following endotoxin administration
monocytes demonstrate an immunotolerant phenotype.16,18,19 The
7-day time point was selected to investigate whether metabolic
changes associated with immunotolerance are persisting over more
extended periods, maybe even after the immunological tolerance
is restored.
2.2 Peripheral bloodmononuclear cells and CD14+
monocyte isolation
Blood was diluted (1:1) in PBS. PBMCs were isolated from blood by
differential density gradient centrifugation over Ficoll-Paque PLUS
(protocol supplied by GE Healthcare, Chicago, IL, USA). Cells were
washed twice in PBS and resuspended in RPMI 1640 culture medium
Dutch modification (Gibco; Thermo Fisher, Waltham, MA, USA),
supplemented with pyruvate (1 mM; Gibco), glutamax (2 mM; Gibco),
and gentamicin (50 𝜇g/ml; Centrafarm, Etten-Leur, the Netherlands).
Classical monocytes were subsequently isolated from the PBMC frac-
tion using magnetic beads labeled with anti-CD14 (protocol: MACS
Miltenyi, Bergisch Gladbach, Germany). Finally, cells were counted
using the Sysmex XN-450 automated differential hematology analyzer
(Sysmex Corporation, Kobe, Japan).
2.3 Ex vivo experiments
Isolated CD14+monocytes were plated in 96-well tissue treated flat-
bottom plates (1.0 × 105 cells/well; Eppendorf, Hamburg, Germany)
and stimulated with RPMI or E. coli LPS (10 ng/ml; serotype 055:B5,
Sigma-Aldrich) for 24 h at 37◦C and 5% CO2. Monocyte cytokine
responses weremeasured in supernatants of 15 endotoxin-challenged
subjects and 6 placebo subjects.
2.3.1 Monocytemetabolic profiling
Metabolic profiling was performed on ex vivo LPS-restimulated and
unstimulated CD14+ monocytes isolated from 5 randomly selected
volunteers that were infused with endotoxin. Samples were placed
in sterile micro centrifuge tubes (2 × 106 cells/tube in a volume of
1 ml). Cell pellets were snap frozen in liquid nitrogen and shipped to
Metabolon (Morrisville, USA). Quantitative measurements of metabo-
lite concentrations were assessed in classical monocytes at baseline,
4 h, and 7 days following endotoxemia. Metabolon performed the
identification and quantification of amino acids, carbohydrates, lipids,
nucleotides,microbiotametabolism, energymetabolism, cofactors and
vitamins, xenobiotics, and novel metabolites.
2.3.2 Ex vivomonocyte oxidative capacity
In the NL61136.091.16 endotoxemia cohort, oxidative burst capac-
ity was determined in isolated CD14+ of 10 male volunteers
(n = 6 endotoxemia challenged, n = 4 placebo). For these exper-
iments, the total production of reactive oxygen species (ROS)
generated by monocytes was measured in flat-bottomed white tissue-
culture treated 96 well plates (Sigma-Aldrich, Saint Louis, MO, USA)
To every well, 20 𝜇l of 3-aminophthalhydrazide, 5-amino-2,3-dihydro-
1,4-phthalazinedione (luminol; 1mMinDMSO;Sigma-Aldrich) inHBSS
(Gibco) and 0.5% BSA (Sigma-Aldrich) were added. Monocytes were
seeded directly inwhite 96-wells plates (1.0× 105 cells/well) and stim-
ulated with 10% human serum opsonized live E. coli (1.0 × 107 bacte-
ria/ml, clinical isolate ATCC35218), S. aureus (1.0 × 107 bacteria/ml,
clinical isolate ATCC25923), C. albicans (1.0 × 107 yeast/ml, strain
UC820), or RPMI. In all experiments, the chemiluminescence was
measured every minute, at 37◦C, by using a BioTek Synergy HT reader
(Winooski, VT, USA) for 1 h.
2.3.3 Monocyte Candida killing capacity
Todetermine the intracellular killing capacityof pathogens after exper-
imental endotoxemia, CD14+ monocytes (1 × 105 cells/well) of 5 male
volunteers were exposed to live C. albicans (2 × 105 yeast/well, strain
UC820) for 24 h at 37◦C and 5%. CO2 at baseline, 4 h after endo-
toxin challenge, and 7 days following endotoxin administration. After
incubation, all cells were lysed in water and serial dilutions of lysates
were plated on Sabouraud agar plates. The Candida killing capacity
of CD14+ monocytes was quantified by counting remaining colony-
forming units (CFUs), after overnight incubation at 37◦C and 5% CO2.
Thepercentageof killedmicrobeswas calculatedas1− (CFUremained
after incubation with microbes/CFU determined before incubation
withmicrobes) × 100.
2.4 In vitromodel for modulation ofmetabolic
pathways
The local ethical board at the Radboud University Nijmegen (Arnhem-
Nijmegen Medical Ethical Committee) approved blood sampling for
the in vitro validation studies usingmetabolic inhibitors. Venous blood
was drawn from healthy volunteers after the healthy volunteers pro-
vided written informed consent. The effect of metabolic modulation
on immune function was studied in experiments using PBMCs. Briefly,
venous blood samples were drawn from healthy volunteers after writ-
ten informed consent was obtained. PBMCs were isolated by den-
sity gradient centrifugation over Ficoll, as described above. Metabolic
inhibitors were selected based on the metabolic changes observed
during endotoxin-induced immunotolerance. First, various metabolic
pathways weremodulated, either inhibited or stimulated, for 24 h. (An
overview is presented in Table 1.) Next, cells were assessed for several
antimicrobial functions.
2.4.1 PBMC stimulation experiments
After24hpreincubationwithmodulators, PBMCs (5.0×105cells/well)
were stimulated with heat-inactivated E. coli (1.0 × 107 bacteria/ml,
clinical isolate ATCC35218), S. aureus (1.0 × 107/ml, clinical isolate
ATCC25923), and C. albicans (1.0 × 106/ml, strain UC820) for 24 h.
Cytokines were measured in supernatants to assess the effects of
metabolic modulation on cytokine responses.
2.4.2 In vitro oxidative burst assays
Similarly, the effects of metabolic modulation on oxidative burst were
determined. Supernatants of seeded PBMCs (5.0 × 105 cells/well)
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TABLE 1 Overview of metabolic modulators used inmodulation experiments
Modulator Target Metabolic pathway inhibitor/stimulator
Experimental
concentration
2DG Hexokinase (competition for glucose) Glycolysis (inhibitor) 11mM
6AN NADP+-dependent enzyme, 6-phosphogluconate dehydrogenase PPP (inhibitor) 100 𝜇M
SOX Lactate dehydrogenase (inhibitor) Pyruvatemetabolism (inhibitor) 40mM
DCA PDC (stimulates pyruvate entry into the tricarboxylic acid cycle) Tricarboxylic acid (TCA) cycle (stimulator) 15mM
OLI ATP synthase ATP synthesis and electron transport
(mitochondrial) (inhibitor)
1 𝜇M
C75 Fatty-acid synthase Fatty acidmetabolism (inhibitor) 40 𝜇M
ETO Carnitine palmitoyltransferase-1 (CPT-1) (inhibitor of fatty acid
oxidation inmitochondria )
Fatty acidmetabolism (inhibitor) 10 𝜇M
NAC Precursor glutathione Glutathione synthesis (stimulator) 20mM
BSO 𝛾-Glutamylcysteine synthetase Glutathione synthesis (inhibitor) 100 𝜇M
BPTES GLS 1 (glutaminase) Glutaminolysis (inhibitor) 50 𝜇M
C968 GLS 1 (glutaminase) Glutaminolysis (inhibitor) 25 𝜇M
DPI Flavoproteins, in particular NADPH oxidase NADPH oxidase complex (inhibitor) 10 𝜇M
were discarded. Subsequently, the PBMCs were stimulated with 200
𝜇l in 10% human serum opsonized live E. coli (1.0 × 107 bacteria/ml,
ATCC35218), S. aureus (1.0× 107 bacteria/ml, ATCC25923),C. albicans
(1.0 × 106 yeast/ml, UC820), or RPMI. ROS production was measured
with a luminol oxidation assay, similarly as described above for ex vivo
experiments.
2.4.3 In vitro NADPH assays
For the detection of intracellular NADPH, isolated PBMCs were
plated in 12-wells flat round-bottom plates with a density of
4.5 × 106 cells/well. PBMCs were preincubated for 24 h with various
modulators, as described before (Table 1). After stimulation for
24 h, stimuli and metabolic modulators were washed away and the
intracellular nucleotide NADPH was measured, using Colorimetric
(450 nm) Quantification Assay Kit following instructions of the manu-
facturer (protocolMAK038: Sigma Aldrich, Saint Louis, MO, USA). The
absorbanceat450nmwasmeasuredusing aBioTekSynergyHTreader
(Winooski, VT, USA) at 37◦C, after a final incubation time of 120min at
room temperature for the conversion of NADP to NADPH.
2.4.4 In vitromicrobial killing assays
After removal of themetabolicmodulators, PBMCswerewashed twice
with warm PBS in order to prevent interference of the metabolic
inhibitors and stimuli with the live C. albicans. PBMCs were stimu-
lated with RPMI, or C. albicans (2 × 105 yeast/well, UC820) for 24 h
at 37◦C and 5% CO2. After incubation, all cells were lysed in water,
and serial dilutions of lysates were plated on Sabouraud agar plates
(Becton Dickinson, Heidelberg, Germany). The Candida killing capacity
of the PBMCs was quantified by counting remaining CFUs overnight
incubation at 37◦C and 5% CO2. The killing capacity was calculated as
described before.
2.4.5 In vitro viability assays
To determine the effect of the inhibitors and stimuli of specific
metabolic pathways on cell viability in PBMCs, apoptosis was assessed
using Annexin-V and propidium iodide (PI) staining. Cells were stained
for 15 min in 300 𝜇l RPMI containing 1 𝜇l Annexin-V (Biovision) and
5 mM CaCl2. Immediately before measurement 1.5 𝜇l PI (Invitrogen
Molecular Probes) was added. Cells were measured using a CytoFLEX
cytometer (Beckman Coulter).
2.5 Cytokinemeasurements
Cytokine measurements of all experiments were performed in col-
lected supernatants that were stored at −20◦C until cytokine mea-
surementswere performed. TNF-𝛼, IL-1𝛽 , IL-1Ra, IL-10, and IL-6 levels
were measured using commercially available ELISAs according to the
protocol supplied by themanufacturer (TNF-𝛼, IL-1𝛽 , and IL-1Ra [R&D
Systems,Minneapolis, MN, USA], IL-10 and IL-6 [Sanquin, Amsterdam,
the Netherlands]).
2.6 Statistical analysis
The data are represented as the mean ± SEM or median, based
on their distribution. One-way ANOVA for repeated measurements
was used to compare statistical differences for the means of the
respective time points. Dunn’s multiple comparison test was used
as a post hoc test. The Wilcoxon signed rank test was performed
to compare means for significant differences of metabolic modula-
tion in validation experiments. Calculations and statistical analysis
were performed with GraphPad Prism Version 5.03 (San Diego, CA,
USA.) All computational analyses for metabolome data analysis were
performed in the R programming language.20 For metabolomics, a
pathway analysis was assessed. Each metabolite was assigned to
a pathway by Metabolon, and enrichments were calculated for these
pathways, comparing two conditions at a time. The conditions that
were compared are 4 h (4h) versus baseline, 7 days (7d) versus 4 h
(4h), and 7 days (7d) versus baseline. The R package "gage" was used to
calculate pathway enrichment, which used log2metabolite concentra-
tions as an input.21 All calculationswere performed in a paired fashion,
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F IGURE 1 Endotoxin-induced monocyte tolerance affects monocyte effector functions. (A) Kinetics of ex vivo LPS-induced IL-1𝛽 , TNF-𝛼,
IL-6, IL-10, and IL-1Ra levels in culture supernatants of CD14+ monocytes that were isolated from healthy volunteers at baseline (BL), 4 h (4h),
and 7 days (7d) after administration of endotoxin (2 ng/kg, red lines, n = 15) or placebo (0.9% saline, black lines, n = 6). Data are presented as
(mean ± SEM) percentage change compared to baseline measurements. Differences within groups over time were analyzed using the Friedmann
test with Dunn’s post hoc test for multiple comparisons. **P < 0.01, ***P < 0.001. (B) Kinetics of ex vivo E. coli, S. aureus, or C. albicans induced ROS
production (AUCrelative lightunits) in isolatedCD14+monocytes fromhealthyvolunteers for all timepoints. Red linespresent subjects challenged
with endotoxin (n = 6); black lines show placebo controls (n = 4). Data are presented as mean ± SEM. Means were compared for significance using
the Friedmann test with Dunn’s post hoc test to illustrate differences between defined time points. *= P< 0.05. (C) Ex vivo intracellular killing of C.
albicans phagocytized by CD14+monocytes isolated at baseline (BL), 4 h (4h) and 7 days (7d) in (n = 5) endotoxin-challenged subjects, presented
for each subject separately. The killing was calculated for duplicates and serial dilutions as 1 – (CFU remained after incubation with microbes/CFU
determined before incubationwithmicrobes)× 100%, hence presented as the percentage ofCandida killing. Data are shown as themean± SEM. BL
versus 4 hwas statistically compared for each subject (*= P< 0.05, **= P< 0.01) with theMann-Whitney U test
andP-valueswere calculatedusinga2-sidedpaired t-test.ABenjamini-
Hochberg false discovery rate procedure was used to correct these
P-values for type I errors.22 Different sample normalization methods
were attempted, including total area normalization, and techniques
more robust to outliers like the normalization method available in the
DESeq2 package.23 In the end, it was found that normalizationwas not
required, since the same amount of sample was used for each mea-
surement, and the values should be semiquantitative. A P-value< 0.05
was considered statistically significant with *P < 0.05, **P < 0.01, and
***P< 0.001.
3 RESULTS
3.1 Endotoxin-induced immunotolerance affects
monocyte cytokine responses, microbial killing
capacity, and oxidative burst
Intravenous endotoxin administration induces immunotolerance in cir-
culating monocytes in healthy volunteers, and these otherwise highly
responsive cells are rendered irresponsive to ex vivo re-challengewith
LPS.16,18,19 Accordingly, we confirmed that monocytes isolated 4 h
after in vivo endotoxin administrationwere irresponsive to ex vivo LPS
stimulation (Fig. 1A). This effect was restored 7 days following endo-
toxemia. In contrast, monocyte cytokine responses to ex vivo LPS stim-
ulation were unaffected in placebo subjects.
After in vivo endotoxin-induced immunotolerance, monocytes
showed a significant attenuated capacity to induce an oxidative burst
response to E. coli and S. aureus (Fig. 1B). A similar trend toward
C. albicans-induced ROS release was observed. Finally, the micro-
bial killing was investigated during endotoxin-induced immunotoler-
ance. After in vivo endotoxin challenge, monocytes showed a reduced
Candida killing capacity in 2/5 subjects (Fig. 1C). The effect of endo-
toxin tolerance on microbial killing in the other volunteers was
inconclusive, with one volunteer showing even enhanced monocyte-
mediated Candida killing during tolerance.
3.2 Endotoxin-induced immunotolerance reduces
themetabolic plasticity of monocytes
Monocytes isolated from 5 volunteers that were infused with endo-
toxin were ex vivo LPS-restimulated or left unstimulated for 24 h.
Metabolic profiling of the monocytes was performed after stimula-
tion at baseline, 4 h postendotoxin infusion, and 7 days postendotoxin
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F IGURE 2 Cellular metabolism during monocyte hyporesponsiveness. (A) Volcano plots representing the –10log of the corrected P-value
(false discovery rate) and the relative mean log 2 fold change for cellular metabolites in monocytes from 5 human endotoxemia subjects. Each of
the panels represents the comparison of ex vivo unstimulated versus ex vivo LPS-stimulated CD14+ monocytes that were isolated at baseline
(BL), 4 h, and 7 days following endotoxemia. Metabolites that demonstrated a mean log2 fold change > 1 or < –1 have been marked in black, and
metabolites that additionally demonstrate a false discovery rate < 0.05 are marked in purple. (B) Venn diagram showing differentially regulated
metabolites for all time points and their relevant overlap. (C) PCA analysis of the metabolic response to ex vivo LPS stimulation. In 5 endotoxemia
subjects log2 fold changes of ex vivo LPS stimulated CD14+monocytes were compared to unstimulated CD14+monocytes isolated and analyzed
for each time point of cell isolation. (D) Heat map of metabolite pathways that were differentially regulated by ex vivo LPS stimulation compared
to ex vivo unstimulated CD14+monocytes, following in vivo endotoxemia. The monocytes were isolated at different time points from 5 subjects
before (BL), and 4 h (4h), or 7 days (7d) after intravenous administration of endotoxin. The mean log2 fold change of each of the groups is plotted
for the various time points. For each pathway, different upregulated (red) or down-regulated (blue) groups of metabolites are presented. *P< 0.05,
**P< 0.01, and ***P< 0.001
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infusion to characterize the metabolic responses to the ex vivo LPS
stimulation. At baseline, when monocytes were still naive, ex vivo
LPS stimulation resulted in a significant upregulation of 40 metabo-
lites in monocytes (Fig. 2A and Table S1). In contrast, in immunotol-
erant monocytes obtained 4 h following in vivo endotoxemia, almost
the full metabolic profile was down-regulated compared to baseline in
untreatedmonocytes (Fig. S1A, left panel). Also ex vivo LPS stimulation
did not significantly upregulate abundance of metabolites; except for
quinolinate, a downstream product of the kynurenine pathway, which
was significantly increased (Fig. 2A, Table S1, and Fig. S1). Monocytes
isolated 7 days following in vivo endotoxin administration showed only
a partially recovered metabolic response upon ex vivo LPS stimula-
tion. A total of 26metabolites were significantly upregulated, of which
13 overlapped with the metabolic response at baseline (Fig. 2B and
Table S1). Principal component analysis (PCA) demonstrated a high
similarity of themetabolic response to ex vivo LPS stimulation at base-
line, but a strong separation of the interindividual metabolic response
during tolerance (Fig. 2C). At 7 days following in vivo endotoxemia,
ex vivo LPS stimulation still did not demonstrated a homogeneous
metabolic response between the subjects (Fig. 2C). Pathway analy-
sis showed induction of multiple central metabolic pathways upon
ex vivo LPS stimulation including glycolysis, pentose phosphate path-
way (PPP), pyruvate metabolism, TCA cycle, glutamate metabolism,
glutathione metabolism, and other circuits involved in amino acid
metabolism (Fig. 2D). Furthermore, numerous pathways were down-
regulated, especially those involved in lipidmetabolism such as biosyn-
thesis of membrane-bound lipids (phospholipids, sphingolipids, and
glycerol-based phospholipids) and fatty acid regulation (Fig. 2D). In
contrast, endotoxin-induced immunotolerance did not displaymodula-
tionof thesemetabolic pathways after ex vivo LPS stimulation. Instead,
the synthesis of dipeptides was highly induced (Fig. 2D). Metabolic
plasticity of ex vivo LPS-stimulated monocytes was only partially
restored 7 days following in vivo endotoxemia with still key metabolic
pathways dysregulated such as glycolysis, TCA cycle, methionine, cys-
teine, S-adenosyl-methionine and taurine metabolism, phospholipid
metabolism, and sphingolipid metabolism. At this time point, ex vivo
LPS stimulation induced down-regulation of the fatty acid metabolism
(acylcarnitine), whereas this pathway was not significantly affected at
other time points (Fig. 2D), which highlights the changed metabolic
response 7 days after endotoxin infusion.
3.3 Modulation of cellular metabolism in naive
immune cells differentially influences cytokine
responses
The metabolic profiling of monocytes indicated a significant loss
of metabolic plasticity in immunotolerant monocytes. Therefore,
the influence of cellular metabolism on immune functions includ-
ing cytokine production, oxidative burst, microbial (Candida) killing,
and cell viability were determined. Metabolic pathways affected
by immunotolerance were systematically targeted by inhibitors/
modulators at crucial steps in the metabolic pathways (Fig. 3A and
Table 1). The effect of each metabolic modulation on cell viability was
measured after 24 h and did not reveal reduced cell viability compared
to their respective vehicle control (Fig. S2). In endotoxin-induced toler-
antmonocytes, loss ofmetabolic plasticity correlatedwith impaired ex
vivo cytokine responses (Figs. 1A and 2D). However, proinflammatory
cytokine responses induced by E. coli, S. aureus, and C. albicans showed
different results after modulation of individual metabolic pathways
in vitro (Fig. 3B–D). None of the metabolic inhibitions reduced E.
coli-induced cytokine responses as expected, but instead increased
cytokine responses were observed (Fig. 3B). Inhibition of glutaminol-
ysis with bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide
(BPTES) significantly reduced TNF-𝛼 concentrations in response to S.
aureus and C. albicans (Fig. 3C and D). Inhibition of the PPP with 6-
aminonicotinamide (6AN) significantly reduced C. albicans-induced IL-
6 production. Inhibition of glycolysis with 2-deoxy-D-glucose (2DG)
showed a trend in reduced C. albicans-induced TNF-𝛼 and IL-1𝛽 pro-
duction (Fig. 3D), but increased E. coli-induced cytokine responses.
Notable, cytokine responses were consistently induced for all three
microbial stimuli after stimulation of the TCA cycle with potassium
dichloroacetate (DCA) (Fig. 3B–D).
3.4 Glycolysis, PPP, and glutaminolysis are crucial
for oxidative burst
The oxidative burst of in vitro LPS-tolerized PBMCs was assessed
to confirm that immunotolerance corresponds with reduced oxida-
tive responses. Indeed reduced ROS release upon microbial restimu-
lation was observed in LPS-tolerized PBMCs (Fig. 4A). The oxidative
burst was assessed by measuring ROS generation in response to E.
coli, S. aureus, and C. albicans after inhibition or simulation of various
metabolic pathways in monocytes. ROS release was diminished upon
inhibition of glycolysis with 2DG, PPP with 6AN, and glutaminolysis
with BPTES or C968. In contrast, inhibition of lactate production with
sodium oxamate (SOX) augmented ROS release. Increasing TCA-cycle
activity with DCA increased oxidative burst in response to C. albicans
exclusively. Albeit being an antioxidant, N-acetylcysteine (NAC) also
increased oxidative burst in response tomicrobial stimulation (Fig. 4B).
Inhibition of pathways known to fuel NADPH (glycolysis, PPP, and
glutaminolysis) reduced ROS release, while modulation of pathways
leading to increased NADPH levels (DCA and NAC) increased ROS
release (Fig. 4C). Measurements of intracellular NADPH levels follow-
ing modulation of these NADPH-dependent pathways validated this.
The blockade of glycolysis using 2DG reduced intracellular NADPH
levels if pyruvate was absent in the media, whereas NAC and DCA
increased intracellular NADPH levels (Fig. 4D). No changes in intracel-
lular NADPH concentrationswere detected by the inhibition of PPP or
glutaminolysis.
3.5 Immunotolerance is associatedwith reduced
Candida killing capacity
In vitro experiments showed a significantly reduced killing capacity
for C. albicans in LPS-induced tolerant monocytes (Fig. 5A). Inhibition
of glycolysis (2DG) did consistently reduce Candida killing capacity in
18 GRONDMAN ET AL.
F IGURE 3 Modulation of cellular metabolism influences monocyte cytokine responses. (A) Schematic overview of the metabolic pathways
that were targeted to study the effects of cellular metabolism on cytokine responses to microbial stimulation. Inhibitors of metabolic pathways
(2DG, 6AN, SOX, OLI, C75, ETO, BSO, BPTES) are indicated with red labels and stimuli of metabolic pathways (DCA and NAC) with green labels.
(B–D) Percentage change in TNF-𝛼, IL-1𝛽 , and IL-6 responses for E. coli (B), S. aureus (C), and C. albicans (D) following inhibition (2DG, 6AN, SOX,
OLI, C75, ETO, BSO, BPTES) or stimulation (DCA and NAC) of designated metabolic pathways compared to the vehicle control of the inhibitor.
2DG (glycolysis, n = 19), 6AN (PPP, n = 11), SOX (pyruvate metabolism, n = 15), DCA (TCA cycle, n = 20), OLI (ATP synthesis, n = 10), C75 (fatty
acid metabolism, n = 13), ETO (fatty acid metabolism, n = 12), NAC (glutathione synthesis, n = 19), BSO (glutathione synthesis, n = 12), and
BPTES (glutaminolysis, n = 12). Data are shown as the median with P-values of statistical comparison by theWilcoxon signed rank test (*P < 0.05,
**P< 0.01, and ***P< 0.001)
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F IGURE 4 Impact ofmodulationofmetabolic pathways on theproductionofROS. (A) In vitroROSproduction inPBMCsafter 24hof preincu-
bationwith LPS (redbars) compared to vehicle control (black bars) upon stimulationwithE. coli, S. aureus, andC. albicans (n=20).Data are expressed
as AUC of emitted light after oxidation of luminescence, presented inmean relative light units with a statistical comparison by theWilcoxon signed
rank test (***P < 0.001). (B) Percentage change in ROS production following inhibition (2DG, -PYR 2DG, 6AN, SOX, OLI, C75, ETO, BSO, BPTES,
and C968) or stimulation (DCA or NAC; green labels) of designated metabolic pathways compared to the vehicle control of the modulator. 2DG
(glycolysis, n=19), -PYR2DG (glycolysis, n=8), 6AN (PPP, n=13), SOX (pyruvatemetabolism, n=14), DCA (TCA cycle, n=18), OLI (ATP synthesis,
(continued on the next page)
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n = 10), C75 (fatty acid metabolism, n = 9), ETO (fatty acid metabolism, n = 15), NAC (glutathione synthesis, n = 14), BSO (glutathione synthesis,
n = 12), BPTES (glutaminolysis, n = 19), and C968 (glutaminolysis, n = 7). Data are shown as the median with P-value of statistical comparison by
the Wilcoxon Signed Rank Test (*P < 0.05, **P < 0.01, and ***P < 0.001). (C) Simplified schematic overview of the metabolic pathways that were
targetedwith inhibitor (green labels) or stimulator (red labels) that could lead to increased intracellular NAPDH levels (green arrows) or decreased
(red dotted line) NADPH levels. (D) Relative changes in monocyte intracellular NADPH levels measured by colorimetric assay following treatment
of the cells for 24 h with various modulators of cellular metabolism (n = 6, red bars). Fold changes are relative to the appropriate vehicle control
(black bars; either RPMI, or RPMI without pyruvate [-PYR], or DMSO). Bars represent the mean ± SEM and were compared for significance using
theWilcoxon Signed Rank Test (*P< 0.05)
healthy donors, but only when pyruvate was excluded from the cul-
ture media during the preincubation period (Fig. 5B). Modulation of
the TCA cycle and PPP did influence Candida killing but showed high
variability between donors. We found that inhibition of glutaminoly-
sis (BPTES or C968) exhibited a substantial impact on Candida killing
in naive monocytes (Fig. 5C). Glutathione precursor NAC augmented
killing capacity in the majority of the donors, whereas other donors
showed unchanged killing capacity. In some donors, killing capacity
waseven reduceduponNACtreatment. Remarkably, experimentswith
reduced or increased glutamine levels in culture media demonstrated
similar trends.
3.6 Reduced oxidative burst inmonocytes
correlates with defectivemicrobial killingmechanisms
Our data demonstrate that central metabolic pathways like glu-
taminolysis and glycolysis are both involved inROSgeneration (Fig. 4B)
and candida killing in naïve monocytes (Fig. 5B and C). The importance
of ROS production for host defense is demonstrated in patients, with
genetic defects in theNADPHoxidase complex, who are unable to pro-
duce ROS and are highly susceptible to staphylococcal and Aspergillus
infections.24 Hypothetically, metabolic modulation might have influ-
enced monocyte antimicrobial functions in similar ways; by altering
NADPH-dependent oxidative burst, thereby influencing phagocytic
activity and killing capacity (Fig. 6A). To test this hypothesis, we inves-
tigated the correlation between C. albicans-induced oxidative burst
and fungal killing (Fig. 6B). In these experiments, C. albicans killing
was measured in the presence of diphenyleneiodonium (DPI). DPI is a
frequently used and potent ROS inhibitor mediated by flavoenzymes,
in particular NADPH oxidase.25 As expected, DPI-treated monocytes
demonstrated drastically reduced capacity to mount an oxidative
burst (Fig. 6C). In parallel, we observed a reduced capacity of mono-
cytes to kill C. albicans yeasts, confirming the link between ROS and
killing (Fig. 6D).
F IGURE 5 Intracellular microbial killing in vitro. (A) In vitro microbial killing capacity by PBMCs after incubation with C. albicans (n = 8) with
24 h pre-exposure (red bars) to LPS compared to media control without LPS (black bars). (B,C) In vitro C. albicans killing in PBMCs after 24 h pre-
exposure to modulators (red bars) of (B) glycolysis (2DG, n = 16, 2DG-PYR, n = 7) TCA cycle (DCA, n = 14), PPP (6AN, n = 12), (C) glutaminolysis
(BPTES, n= 16 or C968, n= 6), glutathione synthesis (NAC, n= 19), or glutaminemetabolism (-glutamine, n= 11, 2xglutamine, n= 8) compared to
the unmodulated situation. All data in this figure are presented as the mean ± SEM and with a significant P-value of statistical comparison by the
Wilcoxon signed rank test (*P< 0.05, **P< 0.01)
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F IGURE 6 Capacity tomount oxidative responses correlates tomicrobial killing. (A) Schematic presentation of the hypothesis howmetabolic
changes can influence the production of ROS (oxidative burst) andmonocyte C. albicans killing capacity. (B) Correlation of oxidative burst assessed
as the integral of the luminesce signal following luminol conversion in response to C. albicans stimulation and C. albicans killing capacity in the per-
centageof killed fungalCFUs inPBMCsof healthydonors (n=6). (C) PBMCsof healthydonors preincubatedwith vehicle control (DMSOblack/gray
lines) or DPI (red lines) for 24 h and subsequently stimulated with opsonized live C. albicans or left unstimulated. Oxidative burst generation was
expressed as luminescence conversion over measured over time (measured every 145 s, during 60min). (D) C. albicans killing capacity in PBMCs of
the same 6 donors after 24 h pre-exposure to DPI, compared to the unmodulated situation (vehicle control). All data in this figure are presented as
themean± SEM andwith a significant P-value of statistical comparison by theWilcoxon signed rank test (*P< 0.05, **P< 0.01)
4 DISCUSSION
This study revealed impaired plasticity of monocytes to modify their
metabolism in response to immunogenic stimulation following in
vivo endotoxin-induced immunotolerance. This was accompanied by
reduced cytokine responses and ROS release, which in some individu-
als was associated with impaired microbial (C. albicans) killing. During
endotoxin-induced immunotolerance, most major metabolic pathways
failed to be modulated in monocytes upon ex vivo LPS restimula-
tion. Even 7 days after endotoxin-induced immunotolerance, major
metabolic pathways including glycolysis and the TCA cycle were not
inducible. This implies a sustained defect in metabolic reprogramming
following in vivo exposure to a bolus endotoxin infusion. Validation
in naive immune cells showed that these pathways were essential
for the immune response to microbial ligands, highlighting the influ-
ence of metabolic modulation on essential antimicrobial functions
in immunotolerance.
Dysregulated glycolysis and oxidative phosphorylation was pos-
tulated as an explanation for the immunological defects of tolerant
monocytes.14 Recently, the metabolic-rewiring signatures during
immunotolerance have been identified in LPS-treated THP-1 cells.15
In line with these findings, we showed a homogeneous metabolic
response of naïve monocytes to ex vivo LPS stimulation. Similarly,
we observed significant differences in metabolic adaptation between
unstimulated andLPS-stimulatedmonocytes in theprogressionof acti-
vation to tolerant and resolution of the inflammatory state. In contrast
to TPH-1 cells,15 we observed heterogeneity in the metabolic respon-
siveness during immunotolerance in healthy subjects. This suggests
that metabolic remodeling is individual-specific. These changes may
even differently correlate with alterations in antimicrobial immune
functions on an individual level. Therefore, individual-specific
metabolic reprogramming might have contributed to the interindi-
vidual variation in monocyte-mediated C. albicans killing among
volunteers infused with endotoxin. When studying sepsis patients, the
interindividual variability may be even more considerable, as a result
of differences in underlying disease and sepsis severity. Therefore,
we propose the need for large multicenter studies that correlate
the interindividual variability of metabolic reprogramming with the
capacity of monocytes to kill microbes. Such multicenter clinical trials
may have enough power to identify metabolic biomarkers that help
to identify high-risk individuals with a predisposition to secondary
infections.
In an attempt to translate pathophysiological mechanisms into clin-
ical practice, we used an in vivo endotoxemia model to simulate the
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biphasic response of sepsis. This model is widely used to study the
early and transient phase of sepsis, illustrated by a controlled systemic
inflammatory response in healthy subjects.26 Endotoxin challenge
induces an immunotolerant state where immune cells are refractory
to ex vivo stimulation, which bears hallmarks of the anti-inflammatory
response seen in sepsis.11 This model enabled the evaluation of com-
prehensive and complex metabolic rewiring in vivo during the bipha-
sic inflammatory response as present in sepsis. However, there are
noteworthy differences between experimental endotoxemia and clini-
cal sepsis that underlines the caution that should be takenwith extrap-
olation of the data to clinical sepsis.
Systemic endotoxin-induced responses in this model are milder
than that suffered by septic patients, who by definition suffer from
organ injury. This is reflectedby the fact that endotoxin-challengedvol-
unteers recover fully without residual deficits and can be discharged
8 h after challenge.16,18,19 In contrast, sepsis-associated organ dys-
function is often life-threatening and assessed in all patients suspected
of sepsis.27 Moreover, severe sepsis survivors have an increased risk
of long-term deficits including physical and cognitive impairment.28
Given that, in experimental endotoxemia, already major (long-lasting)
defects in metabolic plasticity of monocytes were observed, we envi-
sion that during sepsis the severe impact on the immune system may
trigger even more severe changes in cellular metabolism. This possi-
bly contributes to the sustained immune dysfunction in septic patients,
who develop secondary infections days to weeks after diagnosis.7,29
Of note, systemic LPS stimulation can result in opposite immune
responses in vivo.30 Several studies showed that LPS priming with
low concentrations could augment immune responses, resembling in
a proinflammatory phenotype.30–32 However, in line with other endo-
toxemia studies, we showed a proper immunotolerant phenotype in
the current study.16,18,19
Essential metabolic differences were found between homeostasis
and endotoxin-induced immunotolerance, which may reveal biomark-
ers or therapeutic targets for immunoparalysis. The untargeted
metabolome analysis identified the metabolites quinolinate and
kynurenine to be upregulated, respectively 4 h and 7 days after
endotoxin administration. These are metabolites of the tryptophan-
kynurenine pathway, which is known to be activated or dysregulated
in several inflammatory conditions including infectious diseases,
autoimmune disorders, malignancy, and cardiovascular diseases.33
Accumulation of kynurenine and downstream metabolites, through
increased tryptophan degradation by IDO-1, contributes to hypoten-
sion due to vasodilatation, and is therefore considered as a novel
target for septic shock treatment.34 Besides these vascular effects,
alterations in this pathway correlate with disease severity and
impaired immune function.35 Although kynurenines might be linked to
immunoparalysis, whether these metabolites individually can function
as a target to improve immunological function in immunotolerant cells
is yet to be explored.
Cytokine responses are crucial for activation of immune responses,
immune cell recruitment, and initiation of antimicrobial functions. We
confirmed attenuated ex vivo cytokine responses during immuno-
tolerance. Nevertheless, inhibition of specific metabolic pathways,
identified by induction of immunotolerance, did not uniformly impair
cytokine responses in naivemonocytes. Several studies have examined
the effects of glucose metabolism upon LPS or bacterial stimulation
and showed diverse cellular reprogramming depending on the stim-
ulus, experimental setup, and cell population.14,36–39 Glycolysis is
essential for host defense against C. albicans infection.40 Glycolysis
inhibition decreased cytokine response to C. albicans stimulation, but
increased upon E. coli or S. aureus stimulation in our experiments.
These divergent cytokine responses may be the result of differences
in pathogen recognition receptor-mediated signaling pathways, as
well as metabolic changes, induced upon stimulation with crucially
different microbes.39
Oxidative responses are classically linked to the early hyper-
inflammatory phase of sepsis and associate with increased organ
damage.41 However, during monocyte immunotolerance, impaired
ROS production was observed,42 and attenuated superoxide
production was reported after ex vivo restimulation of mono-
cytes from septic patients.43 In line with this, we observed impaired
oxidative burst in immunotolerant monocytes, both ex vivo and in
vitro. The metabolic routes involved in ROS production are glycolysis,
PPP, glutaminolysis, TCA cycle, and glutathione synthesis. Modula-
tion of NADPH-yielding pathways, including glycolysis, glutathione
metabolism, or the TCA cycle influenced intracellular NADPH levels
in our experiments significantly. However, the PPP and glutaminolysis
are considered essential sources of NADPH generation for cells44–46;
controversially, thesewere not significantly altered in our experiments
upon inhibition.
Oxidative burst is crucial for antimicrobial defense.24 In line with
this, we observed a correlation between killing capacity and oxidative
burst in naive monocytes. Similarly, modulation of glutaminolysis and
glycolysis modified both oxidative burst as well as themonocyte killing
capacity. These results support the notion thatmetabolism candirectly
influence immune function, by influencing oxidative burst and micro-
bial (Candida) killing capacity. At the same time, metabolic modulation
inducedhigh variability in intracellular killing betweendonors. This can
partly be explained by the experimental design, in which inhibitors are
washed away after the preincubation period to prevent interference
with themetabolic pathways ofC. albicans. This probably enabled com-
plete or partial restoration of indirectly targeted metabolic pathways,
like glycolysis (2DG) or glutaminemetabolism, as these compounds can
competewith nutrients in the culturemedia like glucose, pyruvate, and
glutamine. In contrast, direct targeting of enzymes like GLS-1 inhibi-
tionbyBPTESorC968may induce less transientmetabolic reprogram-
ming.
Glutamine has gained clinical interest as it has regulatory effects
on immune cell function and may serve as a beneficial supple-
ment in critically ill patients.47 We observed variation in mono-
cyte killing capacity in glutamine poor or supplemented conditions.
In line with this, trials in critically ill patients similarly observed
divergent outcomes upon glutamine supplementation.48,49 Some stud-
ies demonstrated benefits in critically ill patients, including decreased
mortality and infection risk,50–52 but it is now debated that glu-
tamine supplementation can further elucidate hyperinflammation.53
GRONDMAN ET AL. 23
The benefit of modulating glutamine metabolism, therefore, may
depend on the individual inflammatory state. As interference of cel-
lular metabolism can have unpredictable outcomes, studies focusing
on immune cells metabolism and the relation to immune function are
warranted, to avoid harm and identify the patients that could benefit
from targeted therapy.
Remarkably, DCA (TCA cycle stimulator) augmented cytokine
responses to all microbial stimuli in our study. Similar effects were
observed after modulation with NAC (glutathione synthesis). After
exposure to NAC, monocytes also demonstrated augmented oxidative
burst upon S. aureusorE. coli stimulation. Thiswas similar forDCAupon
C. albicans stimulation. These beneficial effects support the potential of
these modulators as novel candidates to reverse immunoparalysis and
will be discussed further in this context.
First, NAC is commonly known as a ROS scavenger and appreci-
ated for its capacity to reduce oxidative stress and organ damage as
well as anti-inflammatory effects. NAC was introduced as an antiox-
idant in SIRS (systemic inflammatory response syndrome) and sepsis
cohorts, but was ineffective in reducing mortality.54 Conversely, high
NAC levels can increase ROS generation in endothelial cells,55 by fuel-
ing glutathione synthesis, this probably results in a pro-oxidant shift in
the glutathione redox state. This pro-oxidant effect is in line with our
results where in most donors augmented antimicrobial functions were
observed with relatively high NAC concentrations.
Second, DCA was used in a clinical trial to treat hyperlactatemia,
which included patients with septic shock, but did not improve
clinical outcome.56 Besides reducing lactate levels, DCA activates the
pyruvate dehydrogenase complex (PDC) and stimulates mitochon-
drial glucose oxidation through increased mitochondrial pyruvate
influx.57 DCA in a sepsis mouse model promoted restoration of
immunometabolism, increased survival, and improved bacterial
clearance.58 New insights and the data presented here suggest
that the modulators DCA and NAC might be reconsiderable tar-
gets in sepsis treatment. However, the aforementioned trials with
DCA and NAC focused on the hyperinflammatory aspects of sepsis.
One can speculate that timing of treatment and the heterogeneity
of populations enrolled in these trials have concealed beneficial
effects in patients subgroups, in particular for patients with profound
immunosuppression. This provides a rationale for future studies
on the use of these metabolic modulators in patients with sepsis-
induced immunoparalysis.
Our study has some limitations. First, metabolomic profiling was
performed in a small number of participants. Therefore, validation
experiments were focused on metabolic pathways rather than on
single metabolites. We assume that parallel to pathway analyses,
individual metabolites may help to identify novel metabolic thera-
peutic targets. Second, our study population was within an age range
of 18–35, whereas 64.9% of cases of sepsis occurs in patients at or
over the age of 65.59 Immune metabolism is a research field that is
relatively new, and knowledge on the differences in immunometabolic
reprogramming between adults and the elderly is scarce. Our results
may, therefore, not be generalizable to populations that commonly
develop sepsis. Third, our sepsismodel focused on the activation of the
innate immune system, although sepsis-induced immunoparalysis is
characterized by defects in both innate and adaptive immunity. Fourth,
our in vitro model was limited to modulate single metabolic pathways
separately. Modulation may also have led to compensatory or alterna-
tive mechanisms for metabolic adaptation. Therefore, this study does
not provide information about the collateral interactions of various
metabolic processes or their connections with molecular, epigenetic,
and transcriptional changes, which all contribute to immunotolerance.
Considering thatmetabolicmodulationmight provide new therapeutic
options for sepsis, a systematic biological approach with validation in
larger endotoxemia and patient cohorts is necessary to unravel the
complexity of metabolic reprogramming and confirm the therapeutic
value of metabolic targets in immune paralysis.
To conclude, this study provides essential insights into metabolic
changes in immunotolerant monocytes, and we report a loss of
metabolic plasticity in these cells. By modulation of metabolic path-
ways in naive immune cells, we validated the concept that metabolic
pathways changed in immunotolerance can affect antimicrobial func-
tions. Furthermore, several metabolites and metabolic pathways were
identified that might represent future therapeutic targets to reverse
sepsis-induced immunoparalysis. As such, this study opens up new
therapeutic avenues for sepsis-induced immunoparalysis.
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